{
  "subset": "contraindication",
  "disease": "Hereditary haemorrhagic telangiectasia",
  "relation": "contraindication",
  "gold_drugs": [
    "aln-6400",
    "bevacizumab",
    "bevacizumab (avastin®)",
    "bevacuzimab spray",
    "caspofungin",
    "doxycycline",
    "doxycycline hyclate",
    "estriol",
    "ferrous sulphate oral tablet",
    "first placebo + than tranexamic acid.",
    "floseal",
    "mupirocin",
    "nacl",
    "nintedanib",
    "nintedanib + soft capsules",
    "octreotide",
    "octreotide lar",
    "oral treatment of placebo soft capsule",
    "pazopanib",
    "pegylated interferon alpha2b",
    "placebo",
    "placebo gel",
    "placebo nasal spray",
    "placebo oral capsule",
    "placebo oral tablet",
    "placebo saline drops",
    "pomalidomide",
    "pomalidomide oral product",
    "propranolol treatment",
    "protopic® 0.1% ointment",
    "ranibizumab",
    "ranibizumab injection ()",
    "sclerotherapy",
    "sirolimus",
    "sodium 0.9%",
    "soy protein isolate",
    "sterile saline",
    "submucosal bevacizumab",
    "tacrolimus capsule",
    "tamoxifen",
    "thalidomide",
    "than placebo + tranexamic acid first",
    "timolol gel",
    "timolol nasal spray",
    "topical timolol",
    "tranexamic acid",
    "vad044 part i",
    "vad044 part ii",
    "vit d"
  ],
  "seeds_initial": [
    "Anticoagulants",
    "Aspirin",
    "Warfarin",
    "Non-steroidal anti-inflammatory drugs (NSAIDs)",
    "Clopidogrel",
    "Ibuprofen",
    "Heparin",
    "Dabigatran",
    "Morphine",
    "Rivaroxaban",
    "Indomethacin",
    "Ticagrelor"
  ],
  "seed_history": [
    [
      "Anticoagulants",
      "Aspirin",
      "Warfarin",
      "Non-steroidal anti-inflammatory drugs (NSAIDs)",
      "Clopidogrel",
      "Ibuprofen",
      "Heparin",
      "Dabigatran",
      "Morphine",
      "Rivaroxaban",
      "Indomethacin",
      "Ticagrelor"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_anticoagulants",
          "name": "Anticoagulants"
        },
        "score": 0.75,
        "graph_snapshot_ref": "GE_H1_round2",
        "key_assumptions": [
          "与出血倾向患者的抗凝风险明确关联"
        ],
        "caveats": [
          "出血风险因素较大，不适用"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_aspirin",
          "name": "Aspirin"
        },
        "score": 0.7,
        "graph_snapshot_ref": "GE_H2_round2",
        "key_assumptions": [
          "影响血小板功能增加出血风险"
        ],
        "caveats": [
          "风险高，且有明显证据"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_warfarin",
          "name": "Warfarin"
        },
        "score": 0.65,
        "graph_snapshot_ref": "GE_H3_round2",
        "key_assumptions": [
          "抗凝剂与出血影响相关"
        ],
        "caveats": [
          "潜在风险需谨慎，应用不推荐"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_non_steroidal_anti_inflammatory_drugs_nsaids",
          "name": "Non-steroidal anti-inflammatory drugs (NSAIDs)"
        },
        "score": 0.6,
        "graph_snapshot_ref": "GE_H4_round2",
        "key_assumptions": [
          "NSAIDs 可能导致出血风险增加"
        ],
        "caveats": [
          "不适合此类患者"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H5",
        "candidate": {
          "id": "drug_clopidogrel",
          "name": "Clopidogrel"
        },
        "score": 0.55,
        "graph_snapshot_ref": "GE_H5_round2",
        "key_assumptions": [
          "出血风险显著"
        ],
        "caveats": [
          "可能导致严重相互作用"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H6",
        "candidate": {
          "id": "drug_ibuprofen",
          "name": "Ibuprofen"
        },
        "score": 0.5,
        "graph_snapshot_ref": "GE_H6_round2",
        "key_assumptions": [
          "可能增加出血风险"
        ],
        "caveats": [
          "风险不容小觑"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H7",
        "candidate": {
          "id": "drug_heparin",
          "name": "Heparin"
        },
        "score": 0.45,
        "graph_snapshot_ref": "GE_H7_round2",
        "key_assumptions": [
          "肝素相关抗凝药物风险高"
        ],
        "caveats": [
          "不适用于此病"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H8",
        "candidate": {
          "id": "drug_dabigatran",
          "name": "Dabigatran"
        },
        "score": 0.4,
        "graph_snapshot_ref": "GE_H8_round2",
        "key_assumptions": [
          "新型抗凝剂风险不容忽视"
        ],
        "caveats": [
          "与患者状态相悖"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H9",
        "candidate": {
          "id": "drug_morphine",
          "name": "Morphine"
        },
        "score": 0.35,
        "graph_snapshot_ref": "GE_H9_round2",
        "key_assumptions": [
          "影响有限但需警惕"
        ],
        "caveats": [
          "可能引发其他出血风险"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H10",
        "candidate": {
          "id": "drug_rivaroxaban",
          "name": "Rivaroxaban"
        },
        "score": 0.3,
        "graph_snapshot_ref": "GE_H10_round2",
        "key_assumptions": [
          "抗凝药物需谨慎使用"
        ],
        "caveats": [
          "证据不足，需要进一步探讨"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H11",
        "candidate": {
          "id": "drug_indomethacin",
          "name": "Indomethacin"
        },
        "score": 0.25,
        "graph_snapshot_ref": "GE_H11_round2",
        "key_assumptions": [
          "NSAIDs风向风险"
        ],
        "caveats": [
          "不适合加入此病患者"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H12",
        "candidate": {
          "id": "drug_ticagrelor",
          "name": "Ticagrelor"
        },
        "score": 0.2,
        "graph_snapshot_ref": "GE_H12_round2",
        "key_assumptions": [
          "抗血小板药的使用风险"
        ],
        "caveats": [
          "与出血风险相关性明显"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→HHT存在明显禁忌",
          "reason": "出血风险及相关性显著，使抗凝剂效果导致的配伍禁忌关系明确"
        }
      ],
      "remaining_gaps": [
        "需要对每种药物的相互作用和出血风险进一步探索"
      ]
    },
    "seed_retrospective": {
      "batches": [
        {
          "round": 1,
          "seeds": [
            "A",
            "B",
            "C",
            "D"
          ],
          "impact_summary": "为抗凝药物相关风险提供了直接证据"
        }
      ],
      "lessons": [
        "在血液疾病相关药物选择中，优先确保对出血风险的评估",
        "应考虑长短期的风险关系"
      ]
    },
    "prompt_patches": [
      {
        "role": "Proponent",
        "patch": "聚焦对出血风险的评估和相关证据"
      },
      {
        "role": "Skeptic",
        "patch": "要求量化出血风险的条件与证据，降低不确定性"
      }
    ],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that are contraindicated or could worsen the rare disease 'Hereditary haemorrhagic telangiectasia'. Return only names."
}